New hope for rare eye disease: faricimab trial targets stubborn retinal deposits
NCT ID NCT07403825
First seen Feb 18, 2026 · Last updated May 20, 2026 · Updated 15 times
Summary
This study tests the drug faricimab in 100 adults aged 50+ with a specific form of wet age-related macular degeneration. The goal is to see if the drug can clear abnormal material under the retina and improve vision. Participants will receive faricimab injections, and the main check happens at 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION, AGE-RELATED are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.